

REMARKS

Any fees that may be due in connection with the filing of this paper or with this application may be charged to Deposit Account No. 06-1050. If a Petition for Extension of time is needed, this paper is to be considered such Petition.

IN THE SEQUENCE LISTING

Attached herewith are a substitute Sequence Listing (23 pages), a computer-readable form of the Sequence Listing on CD-R (labeled as Computer Readable Form REPLACEMENT), and a verified statement that the content of the computer-readable form is identical to the Sequence Listing submitted on paper in accordance with 37 C.F.R §§1.821-1.825. The computer-readable form on CD-R of the Sequence Listing, titled 4905SEQ.004.txt, is identical to the 23 page paper copy and contains no new matter.

Responsive to the Notice to Comply, dated October 16, 2007, SEQ ID NO: 6 and its numeric identifiers are amended to comply with Sequence Listing disclosure rules set forth in 37 C.F.R §§1.821-1.823. Accordingly, the "Xaa" at position 1 and the "Xaa" at position 6 of the amino acid sequence presented in SEQ ID NO: 6 have been removed. According to the WIPO Standard ST.25 (1998), "Xaa" is the equivalent of one unknown or modified amino acid. Applicant inadvertently included an "Xaa" at position 1 and position 6 of SEQ ID NO: 6 as a variable representing each of the N-acetyl chemical group and 7-amino-4-methylcoumarin chemical group, respectively, which are not amino acids. This change to SEQ ID NO: 6 finds basis in the Specification as originally filed at page 22, line 15, where the sequence "IEPD" (as set forth in SEQ ID NO: 6) is presented as having an N-acetyl group at the 5' end and an AMC group (7-amino-4-methylcoumarin) at the 3' end. Other amendments to the Sequence Listing include amendments to the numeric identifiers <211>, <223>, <221>, <222>, and <213> of SEQ ID NO: 6. For example, identifier <211> is amended to reflect the amended sequence length of 4 amino acids. The first and second usage of <223> identifiers of SEQ ID NO: 6 are amended to remove the erroneous references to "Xaa" and now properly refer to the chemical groups as "N-acetyl group attached to 5' end of sequence" and "7-amino-4-methylcoumarin group attached to 3' end of sequence", respectively. The first and second usage of <221> and <222> numeric identifiers in SEQ ID NO: 6 are deleted. The <213> identifier is amended to replace "Homo sapiens" with "Artificial Sequence" and new identifiers <220> and <223> are added to provide a

proper description of the sequence as "Ac-IEPD-AMC substrate". This change finds basis in the Specification as originally filed at page 22, lines 14-15, where the sequence "IEPD" (as set forth in SEQ ID NO: 6) is described as a substrate having an N-acetyl group (Ac) at the 5' end and an AMC group (7-amino-4-methylcoumarin) at the 3' end.

The Sequence Listing is further amended in response to the Notice to Comply at SEQ ID NO: 22. The numeric identifiers for SEQ ID NO: 22 are amended to correctly refer to the N-acetyl chemical group and the AMC chemical group attached to the 5' and 3' ends, respectively, of the DEVD amino acid sequence. Applicant inadvertently categorized the N-acetyl and AMC chemical groups as modified amino acids at position 1 and position 4, respectively. This change to SEQ ID NO: 22 finds basis in the Specification as originally filed at page 53, lines 7, 17, and 28, where the sequence "DEV D" (as set forth in SEQ ID NO: 22) is presented as having an N-acetyl group (Ac) at the 5' end and an AMC group at the 3' end. Accordingly, the numeric identifiers <221>, <222>, and <223> of SEQ ID NO: 22 are amended. For example, the second and third usage of <223> identifiers of SEQ ID NO: 22 are amended to properly refer to the chemical groups as "N-acetyl group attached to 5' end of sequence" and "AMC group attached to 3' end of sequence", respectively. The first and second usage of <221> and <222> numeric identifiers in SEQ ID NO: 22 are deleted.

Further amendments to the Sequence Listing include correction of an obvious typographical error in the fifth usage of the <223> identifier of SEQ ID NO: 29 where "ot" is replaced with "or". An identifier for SEQ ID NO: 54 is amended to correct the location of the second variant "Xaa" amino acid set forth in the second usage of the <222> identifier. Applicant inadvertently identified the second variant amino acid at location 3. According to the amino acid sequence set forth in SEQ ID NO: 54, the second variant amino acid should be at location 2.

Applicant : Nguyen et al.
Serial No. : 10/677,977
Filed : October 2, 2003

Attorney's Docket No.: 19049-005001 / 4905
Amendment and Response to Notice to Comply

These corrections are formal and responsive to the Notice to Comply with Requirements for Patent Application Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures, mailed October 16, 2007. No new matter has been added.

Respectfully submitted,

Stephanie Seidman
Reg. No. 33,779

Attorney Docket No. 19049-005001 / 4905

Address all correspondence to:

Stephanie Seidman
Fish & Richardson P.C.
12390 El Camino Real
San Diego, California 92130
Telephone: (858) 678-4777
Facsimile: (202) 626-7796
email: seidman@fr.com

Applicant : Nguyen et al.
Serial No. : 10/677,977
Filed : October 2, 2003

Attorney's Docket No.: 19049-005001 / 4905
Amendment and Response to Notice to Comply

AMENDMENTS TO THE SEQUENCE LISTING:

Please replace the Sequence Listing in the above-captioned application with the attached substitute Sequence Listing on paper. A replacement compact disc in computer-readable form accompanies this response.